Drug-resistant cytomegalovirus in transplant recipients: A French cohort study

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 12, 2010, Pages 2628-2640

  Hantz, Sébastien ^a,b   Garnier Geoffroy, Françoise ^a   Mazeron, Marie Christine ^c,d   Garrigue, Isabelle ^e   Merville, Pierre ^e   Mengelle, Catherine ^f   Rostaing, Lionel ^f   Marcoux, Franck Saint ^a   Essig, Marie ^a   Rerolle, Jean Philippe ^a   Cotin, Sébastien ^b   Germi, Raphaëlle ^g   Pillet, Sylvie ^h   Lebranchu, Yvon ⁱ   Turlure, Pascal ^a   Alain, Sophie ^a,b  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF LIMOGES   (France)

^c HÔPITAL LARIBOISIÈRE   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f TOULOUSE UNIVERSITY HOSPITAL   (France)

^g GRENOBLE UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

ⁱ UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

CMV; Genotyping; Resistance mutations; Transplantation

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; ARTESUNATE; BENZIMIDAVIR; CIDOFOVIR; CORTICOSTEROID; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN KINASE; PROTEIN KINASE UL 54; PROTEIN KINASE UL 97; TACROLIMUS; UNCLASSIFIED DRUG; VALACICLOVIR; VALGANCICLOVIR;

ADD ON THERAPY; ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL ENDOCARDITIS; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FRANCE; GENE MUTATION; GENE SEQUENCE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HUMAN; IC 50; IMMUNOASSAY; KIDNEY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIDRUG RESISTANCE; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PATIENT MONITORING; PHENOTYPE; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; RECOMMENDED DRUG DOSE; SEROCONVERSION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS DETECTION; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTIVIRAL AGENTS; CHEMOPREVENTION; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; FRANCE; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; ORGAN TRANSPLANTATION; PHENOTYPE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROSPECTIVE STUDIES; VIRAL PROTEINS;

EID: 78149489550     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq368     Document Type: Article

References (37)

1. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601-14.
2. Ljungman P. CMV infections after hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 42 Suppl 1: S70-2.
3. Fishman JA, Emery V, Freeman R et al. Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant 2007; 21: 149-58.
4. Boeckh M, Ljungman P. How we treat CMV in hematopoietic cell transplant recipients. Blood 2009; 113: 5711-9.
5. Humar A, Michaels M. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006; 6: 262-74.
6. Asberg A, Humar A, Jardine AG et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009; 9: 1205-3.
7. Ducancelle A, Belloc S, Alain S et al. Comparison of sequential cytomegalovirus isolates in a patient with lymphoma and failing antiviral therapy. J Clin Virol 2004; 29: 241-7.
8. Schnepf N, Boiteau N, Petit F et al. Rapid determination of antiviral drug susceptibility of human cytomegalovirus by real-time PCR. Antiviral Res 2009; 81: 64-7.
9. Hantz S, Couvreux A, Champier G et al. Conserved domains and structure prediction of human cytomegalovirus UL27 protein. Antivir Ther 2009; 14: 663-72.
10. Alain S, Hantz S, Scieux C et al. Detection of ganciclovir resistance after valaciclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection. J Med Virol 2004; 73: 566-73.
11. Hantz S, Michel D, Fillet AM et al. Early selection of a new UL97 mutant with a severe defect of ganciclovir phosphorylation after valaciclovir prophylaxis and short-term ganciclovir therapy in a renal transplant recipient. Antimicrob Agents Chemother 2005; 49: 1580-3.
12. Wiltshire H, Hirankarn S, Farrell C et al. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 2005; 44: 495-507.
13. Wiltshire H, Paya CV, Pescovitz MD et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005; 79: 1477-83.
14. Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol 2008; 18: 233-46.
15. Erice A, Gil-Roda C, Pérez JL et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 1997; 175: 1087-92.
16. Drew WL, Miner R, Saleh E. Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals. Clin Diagn Virol 1993; 1: 179-85.
17. Chou S, Marousek GI. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. J Virol 2008; 82: 246-53.
18. Scott GM, Weinberg A, Rawlinson WD et al. Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob Agents Chemother 2007; 51: 89-94.
19. Chou S, Lurain NS, Thompson KD et al. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis 2003; 188: 32-9.
20. Cihlar T, Fuller MD, Cherrington JM. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J Virol 1998; 72: 5927-36.
21. Eckle T, Prix L, Jahn G et al. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 2000; 96: 3286-9.
22. Fillet AM, Auray L, Alain S et al. Natural polymorphism of cytomegalovirus DNA polymerase lies in two nonconserved regions located between domains delta-C and II and between domains III and I. Antimicrob Agents Chemother 2004; 48: 1865-8.
23. Humar A, Kumar D, Boivin G et al. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002; 186: 829-33.
24. Boivin G, Goyette N, Rollag H et al. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther 2009; 14: 697-704.
25. Lurain NS, Weinberg A, Crumpacker CS et al. Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. Antimicrob Agents Chemother 2001; 45: 2775-80.
26. Lurain NS, Bhorade SM, Pursell KJ et al. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J Infect Dis 2002; 186: 760-8.
27. Li F, Kenyon KW, Kirby KA et al. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis 2007; 45: 439-7.
28. Eid AJ, Arthurs SK, Deziel PJ et al. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes. Clin Transplant 2008; 22: 162-70.
29. Allice T, Busca A, Locatelli F et al. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: implications for the emergence of drug-resistant cytomegalovirus. J Antimicrob Chemother 2009; 63: 600-8.
30. Limaye AP. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis 2002; 35: 866-72.
31. van der Beek MT, Berger SP, Vossen AC et al. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance. Transplantation 2010; 89: 320-6.
32. Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci USA 2000; 97: 8039.
33. Limaye AP, Raghu G, Koelle DM et al. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185: 20-7.
34. Boutolleau D, Deback C, Bressollette-Bodin C et al. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection. Antiviral Res 2009; 81: 174-9.
35. Perrottet N, Decosterd LA, Meylan P et al. Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. Clin Pharmacokinet 2009; 48: 399-418.
36. Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4: S78-86.
37. Kotton CN, Kumar D, Caliendo AM et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-95.